WINTON GROUP Ltd Has $3.39 Million Stock Position in DaVita Inc. (NYSE:DVA)

WINTON GROUP Ltd lessened its stake in shares of DaVita Inc. (NYSE:DVA) by 48.5% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 22,661 shares of the company’s stock after selling 21,364 shares during the period. WINTON GROUP Ltd’s holdings in DaVita were worth $3,389,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of DVA. MML Investors Services LLC raised its holdings in shares of DaVita by 1.3% during the third quarter. MML Investors Services LLC now owns 5,300 shares of the company’s stock valued at $869,000 after acquiring an additional 68 shares during the period. Exchange Traded Concepts LLC boosted its position in shares of DaVita by 8.3% in the fourth quarter. Exchange Traded Concepts LLC now owns 891 shares of the company’s stock worth $133,000 after buying an additional 68 shares during the period. Impact Partnership Wealth LLC grew its holdings in shares of DaVita by 3.7% during the fourth quarter. Impact Partnership Wealth LLC now owns 1,941 shares of the company’s stock valued at $290,000 after buying an additional 70 shares in the last quarter. Contravisory Investment Management Inc. raised its position in DaVita by 1.2% during the fourth quarter. Contravisory Investment Management Inc. now owns 6,082 shares of the company’s stock valued at $910,000 after buying an additional 73 shares during the period. Finally, Nilsine Partners LLC lifted its stake in DaVita by 0.8% in the 4th quarter. Nilsine Partners LLC now owns 11,160 shares of the company’s stock worth $1,669,000 after acquiring an additional 92 shares in the last quarter. 90.12% of the stock is owned by hedge funds and other institutional investors.

DaVita Stock Up 0.9 %

DaVita stock opened at $152.73 on Friday. The company has a current ratio of 1.26, a quick ratio of 1.21 and a debt-to-equity ratio of 23.18. DaVita Inc. has a 1-year low of $125.64 and a 1-year high of $179.60. The firm’s fifty day simple moving average is $157.71 and its 200-day simple moving average is $157.50. The company has a market capitalization of $12.22 billion, a P/E ratio of 14.22, a P/E/G ratio of 1.07 and a beta of 0.99.

DaVita (NYSE:DVA) last announced its quarterly earnings results on Thursday, February 13th. The company reported $2.24 earnings per share for the quarter, topping analysts’ consensus estimates of $2.14 by $0.10. DaVita had a return on equity of 115.48% and a net margin of 7.31%. Sell-side analysts forecast that DaVita Inc. will post 10.76 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on DVA shares. Sanford C. Bernstein set a $184.00 target price on DaVita in a research note on Friday, February 21st. Cowen reaffirmed a “hold” rating on shares of DaVita in a research report on Tuesday, February 18th. StockNews.com downgraded shares of DaVita from a “buy” rating to a “hold” rating in a research report on Friday, March 21st. Finally, Barclays boosted their price target on shares of DaVita from $164.00 to $169.00 and gave the company an “equal weight” rating in a report on Tuesday, February 18th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and one has assigned a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $166.33.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.